Bank of New York Mellon Corp Takes $1.82 Million Position in Immunome, Inc. (NASDAQ:IMNM)

Bank of New York Mellon Corp acquired a new position in shares of Immunome, Inc. (NASDAQ:IMNM) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 150,100 shares of the company’s stock, valued at approximately $1,816,000. Bank of New York Mellon Corp owned approximately 0.25% of Immunome as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. EntryPoint Capital LLC lifted its position in shares of Immunome by 21,864.0% in the first quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock valued at $136,000 after buying an additional 5,466 shares during the last quarter. Jump Financial LLC acquired a new stake in Immunome during the fourth quarter worth approximately $172,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Immunome during the 2nd quarter worth $206,000. Clear Creek Financial Management LLC increased its position in shares of Immunome by 18.2% in the second quarter. Clear Creek Financial Management LLC now owns 26,188 shares of the company’s stock worth $317,000 after purchasing an additional 4,035 shares during the period. Finally, Sei Investments Co. acquired a new position in Immunome in the first quarter valued at about $469,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Insider Buying and Selling

In related news, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $13.94 per share, with a total value of $97,580.00. Following the transaction, the director now directly owns 16,615 shares of the company’s stock, valued at $231,613.10. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider Jack Higgins sold 3,524 shares of Immunome stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the transaction, the insider now directly owns 16,000 shares in the company, valued at approximately $222,880. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jean Jacques Bienaime acquired 7,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the purchase, the director now owns 16,615 shares in the company, valued at approximately $231,613.10. The disclosure for this purchase can be found here. 8.60% of the stock is currently owned by corporate insiders.

Immunome Trading Down 2.5 %

IMNM opened at $15.40 on Wednesday. The company has a market cap of $923.52 million, a price-to-earnings ratio of -2.04 and a beta of 1.77. The company’s fifty day moving average price is $14.34 and its two-hundred day moving average price is $16.32. Immunome, Inc. has a 1-year low of $6.65 and a 1-year high of $30.96.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The firm had revenue of $2.36 million during the quarter, compared to analysts’ expectations of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. As a group, equities analysts forecast that Immunome, Inc. will post -1.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IMNM has been the subject of several research analyst reports. Piper Sandler lowered their price objective on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Immunome in a report on Tuesday, August 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has an average rating of “Buy” and a consensus price target of $29.00.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.